<DOC>
	<DOC>NCT02294058</DOC>
	<brief_summary>The purpose of this study is to determine whether RPC1063 is effective in the treatment of relapsing multiple sclerosis (RMS).</brief_summary>
	<brief_title>Phase 3 Study of RPC1063 in Relapsing MS</brief_title>
	<detailed_description>The purpose of this study is to learn about the effects and safety of experimental medication RPC1063 taken by mouth in the treatment of Relapsing Multiple Sclerosis (RMS).</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria EDSS score between 0 and 5.0 at baseline â€¢ Primary progressive multiple sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>